ImmunityBio, Inc. - Common Stock (IBRX)

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire founder, Dr. Patrick Soon-Shiong, the company has rapidly evolved into a commercial-stage powerhouse in the immunotherapy landscape. ImmunityBio is currently in focus due to [...]

The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

The standoff ended when the EU granted conditional approval, sending shares up 42% on Wednesday.

On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal scrutiny.

The biopharma outfit's flagship cancer-fighting drug continues to rack up approvals.

The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company.

Koyfin data shows an average 12-month target of $11.8, implying a 96% upside from the stock's current levels.

The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks.

Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade.

The comments come as ImmunityBio pushes for broader global access to Anktiva across indications.

Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock.

ImmunityBio stated that it has not yet achieved median survival in patients receiving Anktiva + CAR-NK treatment in the trial.

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.